ストックスクリーナーアプリを入手
55.27
0.36%
-0.20
アフターアワーズ：
55.27
前日終値:
$55.47
開ける：
$56
24時間の取引高:
1.15M
Relative Volume:
0.55
時価総額：
$10.63B
収益：
$3.24B
当期純損益:
$348.90M
株価収益率:
31.02
EPS:
1.7817
ネットキャッシュフロー:
$717.02M
1週間 パフォーマンス:
-3.37%
1か月 パフォーマンス:
-5.54%
6か月 パフォーマンス:
+4.11%
1年 パフォーマンス:
-7.91%
1日の値動き範囲:
$54.99
$56.05
1週間の範囲:
$53.88
$57.09
52週間の値動き範囲:
$50.76
$66.28
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
名前
Biomarin Pharmaceutical Inc
セクター
電話
(415) 506-6700
住所
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
55.27 | 10.67B | 3.24B | 348.90M | 717.02M | 1.7817 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-20 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | ダウングレード | Stifel | Buy → Hold |
| 2025-09-08 | 開始されました | H.C. Wainwright | Neutral |
| 2025-09-03 | 開始されました | Raymond James | Outperform |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-02-24 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-30 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-20 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 開始されました | Evercore ISI | Outperform |
| 2023-11-15 | 開始されました | Wells Fargo | Overweight |
| 2023-10-23 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 開始されました | Raymond James | Mkt Perform |
| 2023-09-18 | 開始されました | UBS | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-03-21 | 開始されました | Bernstein | Underperform |
| 2023-02-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 開始されました | Citigroup | Neutral |
| 2023-01-30 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2022-10-31 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 再開されました | Wedbush | Neutral |
| 2022-04-25 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-09 | アップグレード | Stifel | Hold → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-04 | 再開されました | Guggenheim | Buy |
| 2021-03-01 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-08-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-08-19 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | ダウングレード | Stifel | Buy → Hold |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 繰り返されました | Citigroup | Buy |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-24 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-04-09 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 繰り返されました | Stifel | Buy |
| 2018-08-03 | 繰り返されました | Stifel | Buy |
すべてを表示
Biomarin Pharmaceutical Inc (BMRN) 最新ニュース
Here Is Why BioMarin (BMRN) Is Projected to Rally - MSN
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy - Seeking Alpha
BioMarin Pharmaceutical stock (US09061G1013): Is rare disease leadership strong enough to unlock new - AD HOC NEWS
Paragon Capital Invests $1.19M in BioMarin Pharmaceutical - National Today
Is BioMarin Pharmaceutical (BMRN) Now Attractive After Prolonged Share Price Weakness? - Yahoo Finance
Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After A 42.7% Three-Year Share Price Fall - Sahm
RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN) - The Globe and Mail
Game Over- No Self-Help Clock Reset for Mandatory Stay Request - The National Law Review
Trading the Move, Not the Narrative: (BMRN) Edition - Stock Traders Daily
BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition - marketscreener.com
BioMarin Pharmaceutical (BMRN) receives FDA approval for expanded use of PALYNZIQ in adolescents - MSN
Perpetual Ltd Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - marketbeat.com
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance Australia
BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BMRN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
BioMarin at TD Cowen Conference: Strategic Growth Amid Challenges - Investing.com
BioMarin Pharmaceutical Inc. (BMRN) rated overweight at Wells Fargo despite Voxzogo phase 2 study discontinuations - msn.com
Here is Why BioMarin (BMRN) is Projected to Rally - Insider Monkey
BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations - Insider Monkey
5 Quality Value Stocks Likely to Make a Comeback According to Analysts - Insider Monkey
BMRN SEC FilingsBiomarin Pharmaceutical Inc 10-K, 10-Q, 8-K Forms - Stock Titan
(BMRN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Exploring High Growth Tech Stocks In The US Market March 2026 - simplywall.st
Vanguard disaggregates holdings; BioMarin (NASDAQ: BMRN) shows 0 shares reported - Stock Titan
BioMarin Bests Ascendis in Appeal Over Patent Suit Stay (1) - Bloomberg Law News
BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Increased to Strong-Buy at Truist Financial - marketbeat.com
BioMarin (BMRN) down 13.6% since last earnings report: Can it rebound? - MSN
Fed. Circ. Rejects Pharma Co. Refiling Suit To Reset Deadline - Law360
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance
BioMarin (BMRN) Down 13.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Assenagon Asset Management S.A. Raises Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Swiss Life Asset Management Ltd Sells 54,282 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin shares drop 4% as Voxzogo trials are discontinued - MSN
RNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Q4 Earnings Highlights: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool
BioMarin Pharmaceutical (BMRN) reports positive results from ongoing trials of VOXZOGO - msn.com
Top 3 Health Care Stocks That Are Set To Fly In March - Benzinga
BioMarin (BMRN) legal chief has 1,273 shares withheld for taxes - Stock Titan
BioMarin (BMRN) CTO reports 1,693-share tax withholding, holds 84,140 - Stock Titan
BioMarin (NASDAQ: BMRN) CFO has 2,117 shares withheld for tax - Stock Titan
BioMarin (BMRN) CEO reports tax-withholding share disposition - Stock Titan
Biomarin Pharmaceutical Inc (BMRN) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):